{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:19:13Z","timestamp":1789003153974,"version":"build-2803163510"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Cancer Society","award":["211617Pj"],"award-info":[{"award-number":["211617Pj"]}]},{"name":"Swedish Cancer Society","award":["210406 JCIA"],"award-info":[{"award-number":["210406 JCIA"]}]},{"name":"The Radiumhemmet Research Fund","award":["211063"],"award-info":[{"award-number":["211063"]}]},{"name":"The Radiumhemmet Research Fund","award":["RaHFo2020"],"award-info":[{"award-number":["RaHFo2020"]}]},{"name":"Stockholm Regional Council","award":["FoUI-962339"],"award-info":[{"award-number":["FoUI-962339"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"crossref","award":["2020-01514"],"award-info":[{"award-number":["2020-01514"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007687","name":"Swedish Medical Society","doi-asserted-by":"crossref","award":["SLS-961466"],"award-info":[{"award-number":["SLS-961466"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2021-02609"],"award-info":[{"award-number":["2021-02609"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Metformin use has been associated with improved survival in patients with different types of cancer, but research regarding the effect of metformin on cutaneous melanoma (CM) survival is sparse and inconclusive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the association between metformin use and survival among patients with CM and diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All adult patients with a primary invasive CM between 2007 and 2014 were identified in the Swedish Melanoma Registry and followed until death, or end of follow-up on 31 December 2017 in this population-based cohort study. Patients with both CM and type 2 diabetes mellitus were assessed further. Overall survival (OS) and melanoma-specific survival (MSS) were the primary endpoints. Cox proportional hazard models estimating crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were used comparing peridiagnostic use vs. nonuse of metformin. Dose response was evaluated based on defined daily doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among a total of 23 507 patients, 1162 patients with CM and type 2 diabetes mellitus were included in the final cohort, with a median follow-up time of 4.1 years (interquartile range 2.4\u20136.1). Peridiagnostic metformin use was associated with a significantly decreased risk of death by any cause (HR 0.68, 95% CI 0.57\u20130.81). Cumulative pre- and postdiagnostic metformin use was also associated with improved OS: the HR for prediagnostic use was 0.90 (95% CI 0.86\u20130.95) for every 6 months of use and the HR for postdiagnostic use ranged from 0.98 (95% CI 0.97\u20130.98) for 0\u20136 months to 0.59 (0.49\u20130.70) for 24\u201330 months of use. No association was found for metformin use and MSS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Metformin use was associated with improved OS in patients with CM and diabetes regardless of timing (pre-, post- or peridiagnostic use) and followed a dose\u2013response pattern. However, further research regarding the underlying mechanisms is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljac003","type":"journal-article","created":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T03:56:20Z","timestamp":1673150180000},"page":"32-40","source":"Crossref","is-referenced-by-count":10,"title":["Association of metformin use and survival in patients with cutaneous melanoma and diabetes"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-8993","authenticated-orcid":false,"given":"Isabelle","family":"Krakowski","sequence":"first","affiliation":[{"name":"Department of Dermatology\/Inflammation Theme"},{"name":"Department of Oncology and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrike","family":"H\u00e4bel","sequence":"additional","affiliation":[{"name":"Institute of Environmental Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Dermatology and Department of Dermatology, Sk\u00e5ne University Hospital , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ingvar","sequence":"additional","affiliation":[{"name":"Surgery, Department of Clinical Sciences, Lund University , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese M L","family":"Andersson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Girnita","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology"},{"name":"Cancer Theme, Medical Unit Head, Neck, Lung and Skin Cancer, Skin Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E","family":"Smedby","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Division of Clinical Epidemiology; Karolinska Institutet , Stockholm , Sweden"},{"name":"Department of Hematology; Karolinska University Hospital , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Oncology and Pathology"},{"name":"Cancer Theme, Medical Unit Head, Neck, Lung and Skin Cancer, Skin Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"2023100517424215200_ljac003-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.suc.2019.09.005","article-title":"Epidemiology and risk factors of melanoma","volume":"100","author":"Carr","year":"2020","journal-title":"Surg Clin North Am"},{"key":"2023100517424215200_ljac003-B2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/djz153","article-title":"Melanoma incidence among non-Hispanic whites in all 50 US states from 2001 through 2015","volume":"112","author":"Thrift","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2023100517424215200_ljac003-B3","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdv.15322","article-title":"Time trends in incidence and mortality of cutaneous melanoma in Germany","volume":"33","author":"Garbe","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100517424215200_ljac003-B4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112838","article-title":"Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in Sweden","volume":"13","author":"Eriksson","year":"2021","journal-title":"Cancers (Basel"},{"key":"2023100517424215200_ljac003-B5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2023100517424215200_ljac003-B6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"2023100517424215200_ljac003-B7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejcsup.2013.07.013","article-title":"Immunotherapy of melanoma","volume":"11","author":"Haanen","year":"2013","journal-title":"EJC Suppl"},{"key":"2023100517424215200_ljac003-B8","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100517424215200_ljac003-B9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2023100517424215200_ljac003-B10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.670726","article-title":"Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy","volume":"11","author":"Trojaniello","year":"2021","journal-title":"Front Oncol"},{"key":"2023100517424215200_ljac003-B11","author":"Socialstyrelsen"},{"key":"2023100517424215200_ljac003-B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2009.09.024","article-title":"Metformin is a potent inhibitor of endometrial cancer cell proliferation \u2013 implications for a novel treatment strategy","volume":"116","author":"Cantrell","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2023100517424215200_ljac003-B13","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.3748\/wjg.14.7192","article-title":"Metformin induces apoptosis of pancreatic cancer cells","volume":"14","author":"Wang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"2023100517424215200_ljac003-B14","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-12-1226-T","article-title":"Metformin blocks melanoma invasion and metastasis development in AMPK\/p53-dependent manner","volume":"12","author":"Cerezo","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2023100517424215200_ljac003-B15","doi-asserted-by":"crossref","first-page":"25808","DOI":"10.18632\/oncotarget.25380","article-title":"Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response","volume":"9","author":"Pereira","year":"2018","journal-title":"Oncotarget"},{"key":"2023100517424215200_ljac003-B16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023100517424215200_ljac003-B17","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-0113","article-title":"Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial","volume":"26","author":"Wang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023100517424215200_ljac003-B18","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.jid.2017.03.033","article-title":"Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma","volume":"137","author":"Kim","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023100517424215200_ljac003-B19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"2023100517424215200_ljac003-B20","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann Oncol"},{"key":"2023100517424215200_ljac003-B21","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","article-title":"Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes","volume":"31","author":"Margel","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023100517424215200_ljac003-B22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1089\/thy.2017.0550","article-title":"Protective effect of metformin against thyroid cancer development: a population-based study in Korea","volume":"28","author":"Cho","year":"2018","journal-title":"Thyroid"},{"key":"2023100517424215200_ljac003-B23","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2553","article-title":"Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"Arrieta","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023100517424215200_ljac003-B24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","article-title":"Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma","volume":"6","author":"Afzal","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2023100517424215200_ljac003-B25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annepidem.2020.09.010","article-title":"The impact of metformin on survival in patients with melanoma \u2013 national cohort study","volume":"52","author":"Urbonas","year":"2020","journal-title":"Ann Epidemiol"},{"key":"2023100517424215200_ljac003-B26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/pcmr.12576","article-title":"Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit","volume":"30","author":"Montaudi\u00e9","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"2023100517424215200_ljac003-B27","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1634\/theoncologist.2019-0518","article-title":"The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"2023100517424215200_ljac003-B28","doi-asserted-by":"crossref","DOI":"10.21873\/anticanres.15620","article-title":"Concurrent nivolumab and metformin in diabetic cancer patients: is it safe and more active?","volume":"42","author":"Ciccarese","year":"2022","journal-title":"Anticancer Res"},{"key":"2023100517424215200_ljac003-B29","author":"SCB, Official Statistics of Sweden"},{"key":"2023100517424215200_ljac003-B30","author":"Regionala Cancercentrum"},{"key":"2023100517424215200_ljac003-B31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish Prescribed Drug Register \u2013 a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2023100517424215200_ljac003-B32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2023100517424215200_ljac003-B33","author":"Socialstyrelsen"},{"key":"2023100517424215200_ljac003-B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"2023100517424215200_ljac003-B35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10654-019-00511-8","article-title":"The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research","volume":"34","author":"Ludvigsson","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"2023100517424215200_ljac003-B36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"2023100517424215200_ljac003-B37","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"Hern\u00e1n","year":"2004","journal-title":"Epidemiol"},{"key":"2023100517424215200_ljac003-B38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/bcpt.12946","article-title":"Considerations for pharmacoepidemiological studies of drug\u2013cancer associations","volume":"122","author":"Potteg\u00e5rd","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2023100517424215200_ljac003-B39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmacoepidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2023100517424215200_ljac003-B40","author":"World Health Organization"},{"key":"2023100517424215200_ljac003-B41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pds.3607","article-title":"Using fractional polynomials to model the effect of cumulative duration of exposure on outcomes: applications to cohort and nested case\u2013control designs","volume":"23","author":"Austin","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023100517424215200_ljac003-B42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2023100517424215200_ljac003-B43","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2023100517424215200_ljac003-B44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143084","article-title":"Diabetes prevalence in Sweden at present and projections for year 2050","volume":"10","author":"Andersson","year":"2015","journal-title":"PLOS ONE"},{"key":"2023100517424215200_ljac003-B45","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/jama.2021.9883","article-title":"Trends in prevalence of diabetes and control of risk factors in diabetes among US adults, 1999\u20132018","volume":"326","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"2023100517424215200_ljac003-B46","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fendo.2018.00472","article-title":"Metformin: focus on melanoma","volume":"9","author":"Jaune","year":"2018","journal-title":"Front Endocrinol (Lausanne"},{"key":"2023100517424215200_ljac003-B47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10654-013-9873-0","article-title":"When the entire population is the sample: strengths and limitations in register-based epidemiology","volume":"29","author":"Thygesen","year":"2014","journal-title":"Eur J Epidemiol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac003\/48517770\/ljac003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/1\/32\/51888811\/ljac003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/1\/32\/51888811\/ljac003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T17:44:09Z","timestamp":1696527849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/1\/32\/6763701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,20]]},"published-print":{"date-parts":[[2023,1,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac003","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1]]},"published":{"date-parts":[[2022,10,20]]}}}